# iRhythm Holdings, Inc.: financial statements, quarterly

IRTC · Nasdaq · CIK 1388658 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/irtc.md) · [Financials](/companies/irtc/financials.md) · [Filings](/companies/irtc/filings.md) · [Insiders](/companies/irtc/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/irtc/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [125](/filings/0001388658-24-000167.md) | [133 d](/filings/0001388658-26-000011.md) | [132](/filings/0001388658-25-000106.md) | [148](/filings/0001388658-25-000196.md) | [148](/filings/0001388658-25-000217.md) | [164 d](/filings/0001388658-26-000011.md) | [159](/filings/0001388658-26-000039.md) | [187](/filings/0001388658-26-000072.md) | [193](/filings/0001388658-25-000217.md) | [209 d](/filings/0001388658-26-000011.md) | [199](/filings/0001388658-26-000039.md) | [224](/filings/0001388658-26-000072.md) |
| Cost of revenue | $m | [42.1](/filings/0001388658-24-000167.md) | [45.1 d](/filings/0001388658-26-000011.md) | [44.4](/filings/0001388658-25-000106.md) | [44.6](/filings/0001388658-25-000196.md) | [46.1](/filings/0001388658-25-000217.md) | [49.3 d](/filings/0001388658-26-000011.md) | [49.5](/filings/0001388658-26-000039.md) | [53.8](/filings/0001388658-26-000072.md) | [55.8](/filings/0001388658-25-000217.md) | [60.8 d](/filings/0001388658-26-000011.md) | [58.0](/filings/0001388658-26-000039.md) | [61.0](/filings/0001388658-26-000072.md) |
| Gross profit | $m | [82.5](/filings/0001388658-24-000167.md) | [87.4 d](/filings/0001388658-26-000011.md) | [87.5](/filings/0001388658-25-000106.md) | [103](/filings/0001388658-25-000196.md) | [101](/filings/0001388658-25-000217.md) | [115 d](/filings/0001388658-26-000011.md) | [109](/filings/0001388658-26-000039.md) | [133](/filings/0001388658-26-000072.md) | [137](/filings/0001388658-25-000217.md) | [148 d](/filings/0001388658-26-000011.md) | [141](/filings/0001388658-26-000039.md) | [163](/filings/0001388658-26-000072.md) |
| Research and development | $m | [16.3](/filings/0001388658-23-000148.md) | [15.4 d](/filings/0001388658-24-000014.md) | [17.0](/filings/0001388658-24-000098.md) | [19.7](/filings/0001388658-24-000143.md) | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Selling, general and administrative | $m | [93.8](/filings/0001388658-24-000167.md) | [100 d](/filings/0001388658-26-000011.md) | [109](/filings/0001388658-25-000106.md) | [107](/filings/0001388658-25-000196.md) | [103](/filings/0001388658-25-000217.md) | [99.8 d](/filings/0001388658-26-000011.md) | [120](/filings/0001388658-26-000039.md) | [126](/filings/0001388658-26-000072.md) | [124](/filings/0001388658-25-000217.md) | [122 d](/filings/0001388658-26-000011.md) | [136](/filings/0001388658-26-000039.md) | [132](/filings/0001388658-26-000072.md) |
| Operating income | $m | [(27.6)](/filings/0001388658-24-000167.md) | [(39.2) d](/filings/0001388658-26-000011.md) | [(38.1)](/filings/0001388658-25-000106.md) | [(23.0)](/filings/0001388658-25-000196.md) | [(50.3)](/filings/0001388658-25-000217.md) | [(4.1) d](/filings/0001388658-26-000011.md) | [(32.6)](/filings/0001388658-26-000039.md) | [(18.7)](/filings/0001388658-26-000072.md) | [(8.4)](/filings/0001388658-25-000217.md) | [2.3 d](/filings/0001388658-26-000011.md) | [(16.2)](/filings/0001388658-26-000039.md) | [(2.5)](/filings/0001388658-26-000072.md) |
| Interest expense | $m | [0.9](/filings/0001388658-23-000148.md) | [0.9 d](/filings/0001388658-24-000014.md) | [2.9](/filings/0001388658-24-000098.md) | [3.3](/filings/0001388658-25-000196.md) | [3.3](/filings/0001388658-25-000217.md) | [3.3 d](/filings/0001388658-26-000011.md) | [3.3](/filings/0001388658-26-000039.md) | [3.3](/filings/0001388658-26-000072.md) | [3.3](/filings/0001388658-25-000217.md) | [3.3 d](/filings/0001388658-26-000011.md) | [3.3](/filings/0001388658-26-000039.md) | [3.3](/filings/0001388658-26-000072.md) |
| Income tax | $m | [0.2](/filings/0001388658-24-000167.md) | [0.3 d](/filings/0001388658-26-000011.md) | [0.0](/filings/0001388658-25-000106.md) | [0.2](/filings/0001388658-25-000196.md) | [0.2](/filings/0001388658-25-000217.md) | [0.2 d](/filings/0001388658-26-000011.md) | [0.7](/filings/0001388658-26-000039.md) | [(0.2)](/filings/0001388658-26-000072.md) | [0.0](/filings/0001388658-25-000217.md) | [0.4 d](/filings/0001388658-26-000011.md) | [0.5](/filings/0001388658-26-000039.md) | [0.0](/filings/0001388658-26-000072.md) |
| Net income | $m | [(27.1)](/filings/0001388658-24-000167.md) | [(38.7) d](/filings/0001388658-26-000011.md) | [(45.7)](/filings/0001388658-25-000217.md) | [(20.1)](/filings/0001388658-25-000217.md) | [(46.2)](/filings/0001388658-25-000217.md) | [(1.3) d](/filings/0001388658-26-000011.md) | [(30.7)](/filings/0001388658-26-000072.md) | [(14.2)](/filings/0001388658-26-000072.md) | [(5.2)](/filings/0001388658-25-000217.md) | [5.6 d](/filings/0001388658-26-000011.md) | [(13.9)](/filings/0001388658-26-000072.md) | [(0.4)](/filings/0001388658-26-000072.md) |
| Diluted EPS | $ per share | [(0.89)](/filings/0001388658-24-000167.md) | not reported | [(1.47)](/filings/0001388658-25-000106.md) | [(0.65)](/filings/0001388658-25-000196.md) | [(1.48)](/filings/0001388658-25-000217.md) | not reported | [(0.97)](/filings/0001388658-26-000039.md) | [(0.44)](/filings/0001388658-26-000072.md) | [(0.16)](/filings/0001388658-25-000217.md) | not reported | [(0.43)](/filings/0001388658-26-000039.md) | [(0.01)](/filings/0001388658-26-000072.md) |
| Basic EPS | $ per share | [(0.89)](/filings/0001388658-24-000167.md) | not reported | [(1.47)](/filings/0001388658-25-000106.md) | [(0.65)](/filings/0001388658-25-000196.md) | [(1.48)](/filings/0001388658-25-000217.md) | not reported | [(0.97)](/filings/0001388658-26-000039.md) | [(0.44)](/filings/0001388658-26-000072.md) | [(0.16)](/filings/0001388658-25-000217.md) | not reported | [(0.43)](/filings/0001388658-26-000039.md) | [(0.01)](/filings/0001388658-26-000072.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Cost of revenue: us-gaap:CostOfRevenue
- Gross profit: us-gaap:GrossProfit
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Selling, general and administrative: us-gaap:SellingGeneralAndAdministrativeExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpense, us-gaap:InterestExpenseNonoperating
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [47.5](/filings/0001388658-24-000167.md) | [36.2](/filings/0001388658-26-000011.md) | [520](/filings/0001388658-25-000106.md) | [551](/filings/0001388658-25-000196.md) | [520](/filings/0001388658-25-000217.md) | [420](/filings/0001388658-26-000011.md) | [375](/filings/0001388658-26-000039.md) | [309](/filings/0001388658-26-000072.md) | [256](/filings/0001388658-25-000217.md) | [236](/filings/0001388658-26-000072.md) | [240](/filings/0001388658-26-000039.md) | [247](/filings/0001388658-26-000072.md) |
| Current assets | $m | [234](/filings/0001388658-23-000148.md) | [231](/filings/0001388658-25-000028.md) | [687](/filings/0001388658-24-000098.md) | [678](/filings/0001388658-24-000143.md) | [628](/filings/0001388658-24-000167.md) | [646](/filings/0001388658-26-000011.md) | [636](/filings/0001388658-25-000106.md) | [664](/filings/0001388658-25-000196.md) | [680](/filings/0001388658-25-000217.md) | [703](/filings/0001388658-26-000072.md) | [681](/filings/0001388658-26-000039.md) | [756](/filings/0001388658-26-000072.md) |
| Total assets | $m | [440](/filings/0001388658-23-000148.md) | [433](/filings/0001388658-25-000028.md) | [910](/filings/0001388658-24-000098.md) | [919](/filings/0001388658-24-000143.md) | [910](/filings/0001388658-24-000167.md) | [931](/filings/0001388658-26-000011.md) | [926](/filings/0001388658-25-000106.md) | [964](/filings/0001388658-25-000196.md) | [995](/filings/0001388658-25-000217.md) | [1,020](/filings/0001388658-26-000072.md) | [1,006](/filings/0001388658-26-000039.md) | [1,093](/filings/0001388658-26-000072.md) |
| Current liabilities | $m | [102](/filings/0001388658-23-000148.md) | [107](/filings/0001388658-25-000028.md) | [96.8](/filings/0001388658-24-000098.md) | [97.9](/filings/0001388658-24-000143.md) | [100](/filings/0001388658-24-000167.md) | [111](/filings/0001388658-26-000011.md) | [111](/filings/0001388658-25-000106.md) | [132](/filings/0001388658-25-000196.md) | [147](/filings/0001388658-25-000217.md) | [152](/filings/0001388658-26-000072.md) | [132](/filings/0001388658-26-000039.md) | [196](/filings/0001388658-26-000072.md) |
| Total liabilities | $m | [220](/filings/0001388658-23-000148.md) | [223](/filings/0001388658-25-000028.md) | [819](/filings/0001388658-24-000098.md) | [820](/filings/0001388658-24-000143.md) | [838](/filings/0001388658-24-000167.md) | [841](/filings/0001388658-26-000011.md) | [839](/filings/0001388658-25-000106.md) | [860](/filings/0001388658-25-000196.md) | [873](/filings/0001388658-25-000217.md) | [867](/filings/0001388658-26-000072.md) | [845](/filings/0001388658-26-000039.md) | [907](/filings/0001388658-26-000072.md) |
| Long-term debt | $m | [34.9](/filings/0001388658-23-000148.md) | [35.0](/filings/0001388658-24-000014.md) | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Current portion of debt | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Shareholders' equity | $m | [220](/filings/0001388658-24-000167.md) | [210](/filings/0001388658-26-000011.md) | [90.3](/filings/0001388658-25-000217.md) | [99.2](/filings/0001388658-25-000217.md) | [71.8](/filings/0001388658-25-000217.md) | [90.9](/filings/0001388658-26-000072.md) | [86.7](/filings/0001388658-26-000072.md) | [104](/filings/0001388658-26-000072.md) | [122](/filings/0001388658-25-000217.md) | [153](/filings/0001388658-26-000072.md) | [161](/filings/0001388658-26-000072.md) | [186](/filings/0001388658-26-000072.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: us-gaap:LongTermDebtNoncurrent
- Current portion of debt: not reported
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [1.2 d](/filings/0001388658-24-000167.md) | [(16.0) d](/filings/0001388658-26-000011.md) | [(52.0)](/filings/0001388658-25-000106.md) | [11.8 d](/filings/0001388658-25-000196.md) | [24.3 d](/filings/0001388658-25-000217.md) | [19.2 d](/filings/0001388658-26-000011.md) | [(7.9)](/filings/0001388658-26-000039.md) | [27.7 d](/filings/0001388658-26-000072.md) | [34.9 d](/filings/0001388658-25-000217.md) | [26.2 d](/filings/0001388658-26-000011.md) | [(26.2)](/filings/0001388658-26-000039.md) | [51.1 d](/filings/0001388658-26-000072.md) |
| Capital expenditure | $m | [9.1 d](/filings/0001388658-24-000167.md) | [13.5 d](/filings/0001388658-26-000011.md) | [9.8](/filings/0001388658-25-000106.md) | [8.5 d](/filings/0001388658-25-000196.md) | [8.8 d](/filings/0001388658-25-000217.md) | [6.8 d](/filings/0001388658-26-000011.md) | [9.4](/filings/0001388658-26-000039.md) | [10.4 d](/filings/0001388658-26-000072.md) | [14.8 d](/filings/0001388658-25-000217.md) | [11.7 d](/filings/0001388658-26-000011.md) | [6.9](/filings/0001388658-26-000039.md) | [13.6 d](/filings/0001388658-26-000072.md) |
| Share repurchases | $m | [0.0 d](/filings/0001388658-24-000167.md) | [0.0 d](/filings/0001388658-26-000011.md) | [25.0](/filings/0001388658-25-000106.md) | [0.0 d](/filings/0001388658-25-000196.md) | [0.0 d](/filings/0001388658-25-000217.md) | [0.0 d](/filings/0001388658-26-000011.md) | [0.0](/filings/0001388658-25-000106.md) | [0.0 d](/filings/0001388658-25-000196.md) | [0.0 d](/filings/0001388658-25-000217.md) | [0.0 d](/filings/0001388658-26-000011.md) | not reported | not reported |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
- Share repurchases: us-gaap:PaymentsForRepurchaseOfCommonStock

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [30.1](/filings/0001388658-23-000148.md) | [30.3](/filings/0001388658-24-000098.md) | [30.5](/filings/0001388658-24-000143.md) | [30.6](/filings/0001388658-24-000167.md) | [31.0](/filings/0001388658-25-000106.md) | [31.1](/filings/0001388658-25-000196.md) | [31.3](/filings/0001388658-25-000217.md) | [31.6](/filings/0001388658-26-000039.md) | [32.0](/filings/0001388658-26-000072.md) | [32.2](/filings/0001388658-25-000217.md) | [32.5](/filings/0001388658-26-000039.md) | [32.9](/filings/0001388658-26-000072.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 32,963,003 at 2026-07-30, from the cover of the [10-Q filed 2026-08-06](/filings/0001388658-26-000072.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:38 ET. No prices; not investment advice.